- CONTACT US
- AFS
- Business
- Bussiness
- Car
- Career
- Celebrity
- Digital Products
- Education
- Entertainment
- Fashion
- Film
- Food
- Fun
- Games
- General Health
- Health
- Health Awareness
- Healthy
- Healthy Lifestyle
- History Facts
- Household Appliances
- Internet
- Investment
- Law
- Lifestyle
- Loans&Mortgages
- Luxury Life Style
- movie
- Music
- Nature
- News
- Opinion
- Pet
- Plant
- Politics
- Recommends
- Science
- Self-care
- services
- Smart Phone
- Sports
- Style
- Technology
- tire
- Travel
- US
- World
Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
How to watch 'A Charlie Brown Christmas' for free this weekend - 2Dangerously cold tonight into Monday
- 3'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- 4Germany's Deutsche Welle broadcaster declared 'undesirable' in Russia
- 59 African migrants died in freezing temperatures near Morocco-Algeria border
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- Europe's powerful Ariane 6 rocket launches Sentinel-1D Earth-observation satellite to orbit (video)
- Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- Cheetos and Doritos to launch new versions without artificial dyes
- FDA adds strongest warning to Sarepta gene therapy linked to 2 patient deaths
- Amazon sued over 'punitive' handling of employee absences
- New Cheetos and Doritos will be free of artificial dyes
- Peloton recalls more than 800,000 bikes after broken seat posts injure users
